ImClone Downgraded

Friedman Billings downgraded ImClone Systems Inc. (IMCL) citing comments from doctors that ImClone's Erbitux lung cancer treatment will not be used to treat the majority of lung cancer patients. The stock price plummeted $4.46 to close at $39.02.